Navigation Links
Viralytics Full Year Financial Results
Date:9/3/2013

ustralia and the UK)

  • Broad anti-cancer activity of CAVATAK™ demonstrated in preclinical setting.
  • Synergistic effect from the combination of CAVATAK™ and Docetaxel.  Potential combination therapy.
  • Combination with either radiation or chemotherapy resulted in more potent anticancer activity in bladder cancer cell lines than radiation or chemotherapy alone.
  • Potent anti-cancer activity in chronic lymphocytic leukaemia (CLL) cell lines.
  • "The 2013 financial year has been one of outstanding progress at Viralytics, which leaves us well positioned to further develop the business in the coming year," said Dr. Malcolm McColl, Chief Executive Officer of Viralytics. "We have achieved key milestones in our Phase 2 CALM study, with interim results demonstrating promising anti-cancer activity. We also had a number of excellent outcomes in our Phase 1 and preclinical programs, demonstrating the broad anti-cancer activity of CAVATAK™.  Our focus is to maintain momentum in clinical development and translate this progress into valuable commercial outcomes."

    About Viralytics Ltd:
    Viralytics is developing oncolytic virotherapy treatments for a range of cancers.  Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21).  CVA21 binds to specific "receptor" proteins highly expressed on multiple cancer types including, but not limited to melanoma, prostate, lung, breast and bladder cancers; and multiple myeloma.  Intratumourally administered CAVATAK™ is currently being studied in a Phase 2 clinical trial in the treatment of Late stage Melanoma (the CALM study) at multiple cancer clinics in the US.  Viralytics also plans to commence a Phase 1/2 study of CAVATAK™ delivered intravenously in patients with melanoma, prostate, lung or metastatic bladder cancers prior to the en
    '/>"/>

    SOURCE Viralytics Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
    2. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
    3. ULURU Inc. Reports Second Quarter 2013 Financial Results
    4. Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
    5. EntreMed Reports Second Quarter 2013 Financial Results
    6. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
    7. Sinovac Reports Unaudited Second Quarter 2013 Financial Results
    8. Vasomedical Announces Financial Results for the Second Quarter of 2013
    9. Nephros Reports Second Quarter 2013 Financial Results
    10. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    11. Dynasil Corporation of America Reports Third Quarter Fiscal 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)... 2014 Research and Markets ... Medical Biosensors Market 2014-2018" report to their ... Medical biosensors are used to analyze ... These biosensors monitor health status, disease betterment, and ... They are cost-effective and user-friendly devices. Also, they ...
    (Date:8/1/2014)... , Aug. 1, 2014 MGC Diagnostics ... company, announced today that it has completed its ... of cardiorespiratory diagnostic products based in Sorinnes, ... served the European cardiorespiratory diagnostics market since 1977. ... of approximately €4.7 million ($6.3 million) and incurred ...
    (Date:8/1/2014)... 1, 2014  Neuland Laboratories Ltd., (NSE:NEULANDLAB; BSE-Scrip ... ingredients (APIs), complex intermediates and custom ... countries, today announced financial results for the first ... 30, 2014. "Neuland,s results in the ... to accommodate certain customer needs, and we do ...
    Breaking Medicine Technology:Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3
    ... presented at Israel Society of Nephrology Conference ... months from single treatment - Data continue to ... expensive injections MISGAV, Israel and LONDON, March 27 ... latest, encouraging results of the Company,s ongoing EPODURE Biopump ...
    ... of Clinical Lipidology publishes largest study comparing cancer ... using FDA database -BOSTON, March 25 A ... ezetimibe mono and ezetimibe/simvastatin combination treatments, compared to ... The study, conducted by Tufts Medical Center ...
    Cached Medicine Technology:Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 2Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 3Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 4Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows 2
    (Date:8/1/2014)... research at Washington University School of Medicine in St. ... in males and frequently are more harmful than similar ... malignant brain tumors, are diagnosed twice as often in ... do not survive as long. , The researchers found ... cancer risk, is significantly less active in male brain ...
    (Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
    (Date:8/1/2014)... 2014 The evolving healthcare landscape ... pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor ... and resources to enhance patient care and profitability. ... critical issues to give independent pharmacists the tools ... , ThoughtSpot show attendance experienced a nearly 70% ...
    (Date:8/1/2014)... Growing prevalence of chronic ailments, ... are boosting healthcare market growth, although a reduction ... increasing generic consumption is a major challenge. , ... 2013, having grown at a Compound Annual Growth ... of the Health Transformation Program (Saglikta Donus, um ...
    (Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Patients with ... pulmonary disease (COPD) have a new weapon to battle ... Thursday. The agency approved a new treatment, ... the third leading killer of Americans. COPD, which is ... as chronic bronchitis and emphysema. Patients with ...
    Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2
    ... Urges Senate to Quickly Pass this Important Lifesaving ... Connor, American Lung Association President and CEO:Today in ... in favor with a strong bipartisan majority for ... the Family Smoking Prevention and Tobacco Control Act ...
    ... Finding could steer caregivers away from situations that would add ... levels of a stress hormone may be responsible for the ... children with a certain type of autism. , ... not experience the normal twofold increase of cortisol upon waking ...
    ... CITY, Mo., April 2 Argus Health Systems, Inc., ... received an award from the Flaspohler Research Group as ... of Interest" in the 2008 PBM Survey of ... ranked by survey participants based on specific attributes, including ...
    ... know where and when patients and staff interact, giving ... influenza transmission patternsATLANTA, April 2 Radianse, Inc. today ... University Hospital Midtown, Atlanta, is using the Radianse ... know early and reliably where, when and with whom ...
    ... 2009 Can we always see what is in front of ... and Cognitive Neuroscience at The City College of New York (CCNY), ... Journal of Neuroscience " by Professor Ro and colleagues from the ... brainwave activity is in a trough. , "We may have our ...
    ... (omega-3s), namely EPA and DHA found in seafood and ... benefits, but evidence of other benefits continues to stack ... menopausal women and healthier weight loss in obese dieters ... these topics are summarized in the March 2009 ...
    Cached Medicine News:Health News:U.S. House of Representatives Again Votes with a Strong Bipartisan Majority in Favor of Granting the U.S. FDA Regulatory Control Over Tobacco Products 2Health News:Asperger Syndrome Tied to Low Cortisol Levels 2Health News:Argus Honored by Flaspohler Research Group as Highest-Rated PBM for 'No Conflicts of Interest' 2Health News:Radianse Announces Real-Time Tracking of Emory ED Staff and Patients to Trace and Contain Infectious Disease Spread 2Health News:Neuroscientists demonstrate link between brainwave acticity and visual perception 2Health News:Omega-3s May Benefit Newborns, Menopausal Women and Obese Individuals 2
    Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
    Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
    Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
    For use with catalog #0454....
    Medicine Products: